RU2001118839A - ANALOGUES GPP-1 - Google Patents
ANALOGUES GPP-1Info
- Publication number
- RU2001118839A RU2001118839A RU2001118839/04A RU2001118839A RU2001118839A RU 2001118839 A RU2001118839 A RU 2001118839A RU 2001118839/04 A RU2001118839/04 A RU 2001118839/04A RU 2001118839 A RU2001118839 A RU 2001118839A RU 2001118839 A RU2001118839 A RU 2001118839A
- Authority
- RU
- Russia
- Prior art keywords
- ala
- hgpp
- seq
- pal
- aib
- Prior art date
Links
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims 69
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 30
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 7
- 125000000923 (C1-C30) alkyl group Chemical group 0.000 claims 6
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 6
- -1 Ala Chemical compound 0.000 claims 4
- 206010012601 Diabetes mellitus Diseases 0.000 claims 4
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 4
- 125000000739 C2-C30 alkenyl group Chemical group 0.000 claims 3
- 125000000052 D-arginine group Chemical group [H]N([H])[C@@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])N([H])C(N([H])[H])=N[H] 0.000 claims 3
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 claims 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 3
- 125000002252 acyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 3
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N L-serine Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 2
- 125000001589 carboacyl group Chemical group 0.000 claims 2
- 125000004642 (C1-C12) alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000000350 Central Nervous System Disease Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims 1
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 1
- 206010018404 Glucagonoma Diseases 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- 208000008466 Metabolic Disease Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 108009000551 Nephrotic syndrome Proteins 0.000 claims 1
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000005333 Pulmonary Edema Diseases 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010038435 Renal failure Diseases 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 201000008779 central nervous system disease Diseases 0.000 claims 1
- 201000006233 congestive heart failure Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 200000000008 restenosis Diseases 0.000 claims 1
- 230000003248 secreting Effects 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Claims (12)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20683398A | 1998-12-07 | 1998-12-07 | |
US11118698P | 1998-12-07 | 1998-12-07 | |
US09/206,833 | 1998-12-07 | ||
US60/111,186 | 1998-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2001118839A true RU2001118839A (en) | 2003-06-27 |
RU2208015C2 RU2208015C2 (en) | 2003-07-10 |
Family
ID=26808707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2001118839/04A RU2208015C2 (en) | 1998-12-07 | 1999-12-07 | Glp-1 analogues |
Country Status (21)
Country | Link |
---|---|
US (2) | US7368427B1 (en) |
EP (2) | EP1992641A3 (en) |
JP (3) | JP2002538081A (en) |
KR (1) | KR100458748B1 (en) |
CN (2) | CN101108878B (en) |
AT (1) | ATE394423T1 (en) |
AU (1) | AU770609B2 (en) |
BR (1) | BR9916027A (en) |
CA (1) | CA2352573C (en) |
CZ (2) | CZ303120B6 (en) |
DE (1) | DE69938669D1 (en) |
DK (1) | DK1137666T5 (en) |
ES (1) | ES2302390T3 (en) |
HU (1) | HUP0104579A3 (en) |
IL (2) | IL143481A0 (en) |
NO (2) | NO330293B1 (en) |
PL (3) | PL393611A1 (en) |
PT (1) | PT1137666E (en) |
RU (1) | RU2208015C2 (en) |
TW (2) | TWI262925B (en) |
WO (1) | WO2000034332A1 (en) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1137666E (en) | 1998-12-07 | 2008-06-02 | Sod Conseils Rech Applic | Glp-1 analogues |
CZ295890B6 (en) | 1998-12-07 | 2005-11-16 | Societe De Conseils De Recherches Et D'application | GLP-1 analogues having aminoisobutyric acid in position 8 and D-arginine in position 36, their use and pharmaceutical compositions in which the analogues are comprised |
EP1305338A2 (en) * | 2000-08-02 | 2003-05-02 | Theratechnologies Inc. | Modified peptides with increased potency |
DK1326630T3 (en) * | 2000-09-18 | 2008-09-15 | Sanos Bioscience As | Use of GLP-2 peptides |
US7371721B2 (en) | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
US7186683B2 (en) | 2000-09-18 | 2007-03-06 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
DE60142351D1 (en) * | 2000-10-20 | 2010-07-22 | Amylin Pharmaceuticals Inc | TREATMENT OF HYPOACTIVE MYOKARD AND DIABETIC HEART MYOPATHY WITH A GLP-1 PEPTIDE |
CA2430934C (en) | 2000-12-01 | 2011-06-21 | Takeda Chemical Industries, Ltd. | A method of producing sustained-release preparations of a bioactive substance using high-pressure gas |
CA2455963C (en) | 2001-07-31 | 2017-07-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1, exendin-4, peptide analogs and uses thereof |
AU2012202081B2 (en) * | 2001-07-31 | 2014-09-25 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 Exendin-4 peptide analogs and uses thereof |
CA2463908A1 (en) | 2001-10-18 | 2003-04-24 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
US7238671B2 (en) | 2001-10-18 | 2007-07-03 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
ATE496940T1 (en) | 2002-07-23 | 2011-02-15 | Ipsen Pharma | GHRELIN ANALOGUE |
WO2004066966A2 (en) * | 2003-01-17 | 2004-08-12 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Peptide yy analogs |
ATE455555T1 (en) * | 2003-02-19 | 2010-02-15 | Ipsen Pharma | GLP-1 ANALOGUE |
CA2741545A1 (en) * | 2003-03-28 | 2004-10-14 | National Institute Of Agrobiological Sciences | Process for producing plant storage organ with high production of recombinant glp-1 and novel recombinant glp-1 |
US7094800B2 (en) | 2003-07-25 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Cyanopyrrolidides, process for their preparation and their use as medicaments |
US7008957B2 (en) | 2003-07-25 | 2006-03-07 | Sanofi-Aventis Deutschland Gmbh | Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments |
US7094794B2 (en) | 2003-07-28 | 2006-08-22 | Sanofi-Aventis Deutschland Gmbh | Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use |
DE10335092B3 (en) | 2003-08-01 | 2005-02-03 | Aventis Pharma Deutschland Gmbh | Substituted benzoylureido-o-benzoylamides, process for their preparation and their use |
WO2005058955A1 (en) * | 2003-12-16 | 2005-06-30 | Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. | Analogues of glp-1 |
AR047776A1 (en) * | 2003-12-16 | 2006-02-22 | Sod Conseils Rech Applic | GLP PHARMACEUTICAL COMPOSITIONS - 1 |
CA2552526A1 (en) | 2004-01-08 | 2005-07-21 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
US7534763B2 (en) | 2004-07-02 | 2009-05-19 | Bristol-Myers Squibb Company | Sustained release GLP-1 receptor modulators |
TW200611704A (en) | 2004-07-02 | 2006-04-16 | Bristol Myers Squibb Co | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
PL1891105T3 (en) * | 2005-06-13 | 2012-09-28 | Imperial Innovations Ltd | Oxyntomodulin analogues and their effects on feeding behaviour |
WO2007051987A1 (en) * | 2005-11-01 | 2007-05-10 | Activotec Spp Limited | Insulinotropic compounds and uses thereof |
WO2007075534A2 (en) | 2005-12-16 | 2007-07-05 | Nektar Therapeutics Al, Corporation | Polymer conjugates of glp-1 |
US8288339B2 (en) | 2006-04-20 | 2012-10-16 | Amgen Inc. | GLP-1 compounds |
EP2021014A1 (en) | 2006-05-26 | 2009-02-11 | Brystol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
ES2628063T3 (en) * | 2007-01-05 | 2017-08-01 | Indiana University Research And Technology Corporation | Glucagon analogs showing greater solubility in physiological pH buffers |
JP2010538069A (en) * | 2007-09-07 | 2010-12-09 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | Exendin-4 and analogs of exendin-3 |
MX2010012695A (en) * | 2008-06-17 | 2011-03-15 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers. |
WO2010076809A2 (en) * | 2008-12-29 | 2010-07-08 | Panacea Biotec Ltd | Glp-1 analogs and uses thereof |
US8778872B2 (en) * | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
WO2012054861A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Glp-1 polymer conjugates having a releasable linkage |
WO2012054822A1 (en) | 2010-10-22 | 2012-04-26 | Nektar Therapeutics | Pharmacologically active polymer-glp-1 conjugates |
WO2012166951A1 (en) | 2011-05-31 | 2012-12-06 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
BR112014013925B1 (en) | 2011-12-12 | 2022-02-22 | Receptos Llc | glp-1 receptor modulating compounds and pharmaceutical composition and combination comprising said compounds |
CN102584982B (en) * | 2012-02-10 | 2014-02-05 | 深圳翰宇药业股份有限公司 | Method for purifying solid-phase synthetic coarse liraglutide |
WO2014010586A1 (en) | 2012-07-10 | 2014-01-16 | 武田薬品工業株式会社 | Pharmaceutical preparation for injection |
KR102229051B1 (en) | 2013-05-28 | 2021-03-16 | 다케다 야쿠힌 고교 가부시키가이샤 | Peptide compound |
CN103285379A (en) * | 2013-06-09 | 2013-09-11 | 南方医科大学 | Use of GLP-1 (Glucagon-Like Peptide-1) for preparing medicines for preventing and treating macrovascular complications of type 2 diabetes |
BR112015031040A8 (en) | 2013-06-11 | 2018-01-02 | Receptos Inc | NEW GLP-1 RECEIVER MODULATORS |
EP3172199B1 (en) | 2014-07-25 | 2020-07-01 | Celgene International II Sarl | Pyrimidine derivatives as glp-1 receptor modulators |
JP2018012644A (en) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | Peptide compound |
KR102497644B1 (en) | 2014-12-10 | 2023-02-08 | 리셉토스 엘엘씨 | Glp-1 receptor modulators |
MX2017011586A (en) | 2015-03-09 | 2017-10-26 | Intekrin Therapeutics Inc | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy. |
EP3394104A2 (en) | 2015-12-23 | 2018-10-31 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists |
JP7026044B2 (en) | 2015-12-23 | 2022-02-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Long-acting GLP-1r agonist for the treatment of neurological and neurodegenerative conditions |
CA3024962A1 (en) | 2016-05-24 | 2017-11-30 | Takeda Pharmaceutical Company Limited | Peptide compound |
JP2019520336A (en) * | 2016-06-02 | 2019-07-18 | インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション | Water soluble and chemically stable glucagon peptide |
JOP20190177A1 (en) | 2017-01-17 | 2019-07-16 | Amgen Inc | Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr) |
CA3058806A1 (en) | 2017-04-03 | 2018-10-11 | Coherus Biosciences Inc. | Ppar.gamma. agonist for treatment of progressive supranuclear palsy |
CN109942696A (en) * | 2017-12-21 | 2019-06-28 | 中国药科大学 | Long-actingization glucagon-like-peptide-1 (GLP-1) analog and its application |
CN116970062B (en) * | 2022-04-29 | 2024-04-09 | 南京知和医药科技有限公司 | Ultra-long acting GLP-1 polypeptide derivative and preparation method and application thereof |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1539498A (en) | 1925-05-26 | And fifteen | ||
CA2073856C (en) * | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
DK36392D0 (en) * | 1992-03-19 | 1992-03-19 | Novo Nordisk As | USE OF CHEMICAL COMPOUND |
AU671117B2 (en) * | 1992-06-15 | 1996-08-15 | Scios Inc. | Glucagon-like peptide and insulinotropin derivatives |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
CA2243718A1 (en) * | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
ATE356830T1 (en) * | 1996-08-30 | 2007-04-15 | Novo Nordisk As | GLP-1 DERIVATIVES |
US6458924B2 (en) | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US5916883A (en) | 1996-11-01 | 1999-06-29 | Poly-Med, Inc. | Acylated cyclodextrin derivatives |
UA65549C2 (en) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight |
WO1998043658A1 (en) * | 1997-03-31 | 1998-10-08 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
WO1999043705A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | N-terminally truncated glp-1 derivatives |
FR2777283B1 (en) | 1998-04-10 | 2000-11-24 | Adir | NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
PT1137666E (en) | 1998-12-07 | 2008-06-02 | Sod Conseils Rech Applic | Glp-1 analogues |
CZ295890B6 (en) | 1998-12-07 | 2005-11-16 | Societe De Conseils De Recherches Et D'application | GLP-1 analogues having aminoisobutyric acid in position 8 and D-arginine in position 36, their use and pharmaceutical compositions in which the analogues are comprised |
WO2001035988A1 (en) | 1999-11-12 | 2001-05-25 | Novo Nordisk A/S | Use of glp-1 agonists for the inhibition of beta cell degeneration |
-
1999
- 1999-12-07 PT PT99960657T patent/PT1137666E/en unknown
- 1999-12-07 CZ CZ20011895A patent/CZ303120B6/en not_active IP Right Cessation
- 1999-12-07 EP EP08005960A patent/EP1992641A3/en not_active Withdrawn
- 1999-12-07 CN CN2007101410499A patent/CN101108878B/en not_active Expired - Fee Related
- 1999-12-07 HU HU0104579A patent/HUP0104579A3/en unknown
- 1999-12-07 CZ CZ20120110A patent/CZ303399B6/en not_active IP Right Cessation
- 1999-12-07 PL PL393611A patent/PL393611A1/en unknown
- 1999-12-07 CA CA2352573A patent/CA2352573C/en not_active Expired - Fee Related
- 1999-12-07 US US09/856,676 patent/US7368427B1/en not_active Expired - Fee Related
- 1999-12-07 ES ES99960657T patent/ES2302390T3/en not_active Expired - Lifetime
- 1999-12-07 DE DE69938669T patent/DE69938669D1/en not_active Expired - Lifetime
- 1999-12-07 JP JP2000586774A patent/JP2002538081A/en active Pending
- 1999-12-07 KR KR10-2001-7007050A patent/KR100458748B1/en not_active IP Right Cessation
- 1999-12-07 WO PCT/US1999/028929 patent/WO2000034332A1/en active Application Filing
- 1999-12-07 EP EP99960657A patent/EP1137666B9/en not_active Expired - Lifetime
- 1999-12-07 BR BR9916027-7A patent/BR9916027A/en not_active IP Right Cessation
- 1999-12-07 AU AU17512/00A patent/AU770609B2/en not_active Ceased
- 1999-12-07 CN CNB998141852A patent/CN100334109C/en not_active Expired - Fee Related
- 1999-12-07 PL PL385112A patent/PL208751B1/en unknown
- 1999-12-07 DK DK99960657T patent/DK1137666T5/en active
- 1999-12-07 RU RU2001118839/04A patent/RU2208015C2/en not_active IP Right Cessation
- 1999-12-07 IL IL14348199A patent/IL143481A0/en unknown
- 1999-12-07 PL PL349609A patent/PL205713B1/en unknown
- 1999-12-07 AT AT99960657T patent/ATE394423T1/en active
-
2000
- 2000-01-07 TW TW088121393A patent/TWI262925B/en not_active IP Right Cessation
- 2000-01-07 TW TW095106593A patent/TWI339208B/en not_active IP Right Cessation
-
2001
- 2001-05-31 IL IL143481A patent/IL143481A/en not_active IP Right Cessation
- 2001-06-06 NO NO20012787A patent/NO330293B1/en not_active IP Right Cessation
-
2005
- 2005-10-13 JP JP2005298418A patent/JP2006077022A/en active Pending
-
2008
- 2008-05-06 US US12/115,976 patent/US20090149378A1/en not_active Abandoned
-
2009
- 2009-08-14 JP JP2009188046A patent/JP2010001301A/en active Pending
-
2010
- 2010-03-04 NO NO20100307A patent/NO20100307L/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2001118839A (en) | ANALOGUES GPP-1 | |
RU2208015C2 (en) | Glp-1 analogues | |
RU2001118855A (en) | ANALOGUES GLP-1 | |
RU2003112447A (en) | ANALOGUES GLP-1 | |
CA2122340C (en) | Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs | |
RU99106518A (en) | GLP-1 DERIVATIVES | |
US5717062A (en) | Cyclic analogs of PTH and PTHrP | |
CA2378431A1 (en) | Peptides that lower blood glucose levels | |
JP2010535781A (en) | Treatment for obesity | |
JPH07116229B2 (en) | Peptides with biological activity that are structurally related to regions within growth hormone | |
JP2019534248A (en) | Amylin analog | |
CN107567459A (en) | Amylin analogs | |
JP2010174016A (en) | Analogue of glp-1 | |
JP7295871B2 (en) | Modified lipidated relaxin B chain peptides and their therapeutic uses | |
AU2023203430A1 (en) | Novel glp-1 analogues | |
AR043365A1 (en) | GLP-1 ANALOGS | |
TW201940504A (en) | Modified lipidated Relaxin B chain peptides and their therapeutic use | |
Balasubramaniam et al. | Structure− activity studies including a ψ (CH2-NH) scan of peptide YY (PYY) active site, PYY (22− 36), for interaction with rat intestinal PYY receptors: development of analogues with potent in vivo activity in the intestine | |
AR076950A2 (en) | ANALOGS OF THE 1-SIMILAR PEPTIDE TO GLUCAGON USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
CA2768016A1 (en) | Glp-1 analogues | |
Nakamura et al. | Some Aspects of the Relationship between N-Terminal Structure and MSH Activity of Three Decapeptides Related to ACTH A Comparative Study of Gly 1-ACTH (1-10) OH, Ibu 1-ACTH (1-10) OH and β-Ala 1-ACTH (1-10) OH | |
Weigent et al. | Growth hormone effects on the immune system | |
CN116970064A (en) | GLP-1/GCG receptor co-agonists, pharmaceutical compositions comprising same and uses thereof | |
JPH08176191A (en) | Synthetic peptide derivative or its salt | |
MXPA97009098A (en) | Chemical analogues of body grease-pro with biological power increment |